Table 8.
Conditional GWAS Analysis on the Use of CVD and Antidepressant Medications
| Risk locus | Conditional medication |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| C01D Vasodilators used in cardiac diseases | C02 Antihypertensives | C03 Diuretics | C07 Beta blocking agents | C08 Calcium channel blockers | C09 Agents acting on the renin-angiotensin system | C10AA HMG CoA reductase inhibitors | N06A Antidepressants | ||
| rs6899057 (IBS) ADCY2 |
OR | 1.07 (1.04 - 1.09) | |||||||
| P | 2.0E-08 | ||||||||
| OR-cond | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.06 (1.04–1.09) | |
| P-cond | 1.2E-07 | 2.4E-08 | 9.1E-09 | 8.0E-09 | 1.2E-08 | 1.3E-08 | 1.4E-08 | 2.6E-07 | |
| rs6899057 (IBS-M) ADCY2 |
OR | 1.09 (1.05–1.12) | |||||||
| P | 2.3E-08 | ||||||||
| OR-cond | 1.09 (1.05–1.12) | 1.09 (1.05–1.12) | 1.09 (1.05–1.12) | 1.09 (1.06–1.12) | 1.09 (1.05–1.12) | 1.09 (1.05–1.12) | 1.09 (1.05–1.12) | 1.08 (1.05–1.11) | |
| P-cond | 8.3E-08 | 2.5E-08 | 1.9E-08 | 1.4E-08 | 2.2E-08 | 2.2E-08 | 2.0E-08 | 1.1E-07 | |
| rs2048419 (IBS-M) CLDN23 / MFHAS1 |
OR | 1.08 (1.05–1.11) | |||||||
| P | 4.4E-08 | ||||||||
| OR-cond | 1.08 (1.05–1.11) | 1.08 (1.05–1.11) | 1.08 (1.05–1.11) | 1.08 (1.05–1.11) | 1.08 (1.05–1.11) | 1.08 (1.05–1.11) | 1.08 (1.05–1.11) | 1.07 (1.04–1.10) | |
| P-cond | 1.4E-07 | 1.5E-08 | 2.7E-08 | 1.8E-08 | 4.0E-08 | 3.2E-08 | 3.5E-08 | 1.0E-06 | |
| rs2035380 (IBS) BMAL1 |
OR | 1.07 (1.04–1.09) | |||||||
| P | 3.1E-08 | ||||||||
| OR-cond | 1.07 (1.04–1.10) | 1.07 (1.05–1.10) | 1.07 (1.05–1.10) | 1.07 (1.05–1.10) | 1.07 (1.04–1.10) | 1.07 (1.05–1.10) | 1.07 (1.05–1.10) | 1.07 (1.04–1.10) | |
| P-cond | 1.8E-07 | 2.8E-08 | 1.5E-08 | 3.0E-09 | 2.5E-08 | 1.4E-08 | 1.6E-08 | 1.5E-07 | |
| rs9517497 (IBS) DOCK9 |
OR | 1.07 (1.04–1.09) | |||||||
| P | 2.3E-08 | ||||||||
| OR-cond | 1.06 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.07 (1.04–1.09) | 1.06 (1.04–1.09) | 1.07 (1.05–1.10) | |
| P-cond | 5.9E-07 | 2.7E-08 | 1.4E-08 | 3.6E-08 | 2.5E-08 | 2.6E-08 | 3.8E-08 | 9.5E-09 | |
NOTE. Conditional analyses used GWAS summary-level data on the use of CVD and antidepressant medications, obtained from Wu et al21 (PMID:31015401).
CoA, coenzyme A; CVD, cardiovascular diseases; GWAS, genome-wide association study; HMG, 3-hydroxy-3-methylglutaryl; IBS, irritable bowel syndrome; IBS-M, irritable bowel syndrome mixed subtype; OR, odds ratio (with 95% confidence interval) of the associated lead SNP for the discovery IBS and IBS-M GWAS; OR-cond, odds ratio (with 95% confidence interval) of the associated lead SNP after conditioning IBS/IBS-M GWAS results on medication use.